125
Participants
Start Date
December 31, 2006
Primary Completion Date
October 31, 2008
Study Completion Date
October 31, 2008
Ocriplasmin 25µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
Ocriplasmin 75µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
Ocriplasmin 125µg
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
Placebo
Intravitreal injection of placebo
Columbia University - Harkness Eye Institute, New York
Retina Vitreous Surgeons of Central NY, New York
Allegheny Ophthalmic & Orbital Associates, P.C., Pittsburgh
Duke Eye Center, Durham
Center for Retina and Macular Disease, Winter Haven
National Ophtlamic Research Institute, Fort Meyers
Retina Association of Cleveland, Lakewood
Associated Retinal Consultants, P.C., Royal Oak
Vitroretinal Surgery, PA, Minneapolis
Rush University Med. Ctr, Chicago
Vitreoretinal Consultants, Houston
Valley Retina Institute, P.A., McAllen
Retina Centers, P.C., Tucson
Jules Stein Eye Institute/UCLA, Los Angeles
Retinal Consultants of San Diego, Poway
VMR Institute, Huntington Beach
Retinal Consultants Medical Group, Sacramento
Mailing add: New England Eye Center - Tufts, Boston
Retina Vitreous Centre, PA, New Brunswick
Vanderbilt Eye Institute, Nashville
Lead Sponsor
ThromboGenics
INDUSTRY